Alnylam Pharmaceuticals, Inc. ALNY | NASDAQ
Next Earnings: Jul 30, 2025
Company Overview:
6.4 Year ALNY Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
ALNY Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for ALNY
Based on past 6.4-year performance, here are ALNY growth metrics:
Share price CAGR of +23.44%
Dividend CAGR of +0%
Using ALNY CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ALNY (DRIP) | ALNY - No DRIP | |
|---|---|---|
| Current Price | $321.49 | $321.49 |
| Start Shares | 31.11 | 31.11 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 31.11 | 31.11 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $2,139.34 | $321.49 |
| Total Dividends | $0 | $0 |
| Final Value | $66,545 | $10,000 |
NOTE: Above numbers are our estimate based on ALNY's Dividend and Price CAGR over past 6.4 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Alnylam Pharmaceuticals, Inc. (ALNY) had its IPO on 2004-06-01, and is trader on NASDAQ stock exchange.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY website: https://www.alnylam.com
